Late-breaking trials, first report investigations announced for TCT

The Cardiovascular Research Foundation has announced the lineup for the late-breaking trials and first report investigations for this year’s Transcathether Cardiovascular Therapeutics Scientific Symposium.

The meeting, which will take place from Sept. 13 to 17 in Washington, D.C., will highlight a wide range of device- and pharmaceutical-based advancements in the field of interventional cardiology.

The first day of plenary sessions on Sept. 13 will feature the results of several trials assessing transcatheter aortic valve replacement. Among them are the 5-year results of the PARTNER I trial, which examined TAVR with the Sapien valve (Edwards Lifesciences) vs. conservative care in high-risk patients with aortic stenosis; and a cost-effectiveness analysis of the CoreValve High Risk trial that looked at TAVR with the CoreValve (Medtronic) vs. surgical AVR in high-risk patients with aortic stenosis.

Other trials that will be presented during the 4 days of plenary sessions include:

  • The prospective, randomized SECURITY trial testing 6-month vs. 12-month duration of dual antiplatelet therapy after drug-eluting stent implantation;
  • The TRANSLATE-ACS large-scale registry evaluating patterns of use and 1-year outcomes with prasugrel (Effient, Daiichi Sankyo/Eli Lilly) vs. clopidogrel in patients with acute MI undergoing PCI;
  • The prospective, randomized ABSORB II trial, comparing an everolimus-eluting bioresorbable scaffold with an everolimus-eluting stent in patients with CAD;
  • The prospective, randomized, sham-controlled Symplicity Flex trial of renal sympathetic denervation in patients with refractory hypertension;
  • The prospective, randomized OCT STEMI trial, which is examining optical coherence tomography guidance during primary PCI for acute MI;
  • The prospective, randomized PRIMA trial assessing patent foramen ovale closure in patients with refractory migraine with aura;
  • The prospective, randomized EXCITE ISR trial looking at excimer laser atherectomy vs. balloon angioplasty for femoropopliteal in-stent restenosis.

Stay tuned to for more news on TCT 2014 as it becomes available.